Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Subject
Sign on to:
My Account
Receive email
updates
Edit Profile
CMU Intellectual Repository
Browsing by Author Esmelda Montalban
Jump to:
0-9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or enter first few letters:
Sort by:
title
issue date
submit date
In order:
Ascending
Descending
Results/Page
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Authors/Record:
All
1
5
10
15
20
25
30
35
40
45
50
Showing results 2 to 3 of 3
< previous
Issue Date
Title
Author(s)
1-Sep-2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
Beatriz Grinsztejn
;
Michael D. Hughes
;
Justin Ritz
;
Robert Salata
;
Peter Mugyenyi
;
Evelyn Hogg
;
Linda Wieclaw
;
Robert Gross
;
Catherine Godfrey
;
Sandra W. Cardoso
;
Aggrey Bukuru
;
Mumbi Makanga
;
Sharlaa Faesen
;
Vidya Mave
;
Beatrice Wangari Ndege
;
Sandy Nerette Fontain
;
Wadzanai Samaneka
;
Rode Secours
;
Marije van Schalkwyk
;
Rosie Mngqibisa
;
Lerato Mohapi
;
Javier Valencia
;
Patcharaphan Sugandhavesa
;
Esmelda Montalban
;
Anchalee Avihingsanon
;
Breno R. Santos
;
Nagalingeswaran Kumarasamy
;
Cecilia Kanyama
;
Robert T. Schooley
;
John W. Mellors
;
Carole L. Wallis
;
Ann C. Collier
;
B. Grinsztejn
;
P. N. Mugyenyi
;
A. Collier
;
R. Salata
;
C. Godfrey
;
E. Hogg
;
M. Hughes
;
J. Ritz
;
L. Wieclaw
;
T. Sise
;
J. W. Mellors
;
C. Wallis
;
C. V. Fletcher
;
M. Gandhi
;
R. Gross
;
R. T. Schooley
;
R. Walensky
;
M. van Schalkwyk
;
S. Faesen
;
R. Mngqibisa
;
J. Valencia
;
E. Montalban
;
N. Kumarasamy
;
C. Kanyama
;
S. W. Cardoso
;
B. R. Santos
;
B. Mansfield
;
H. Mugerwa
;
B. W. Ndege
;
R. Secours
;
W. Samaneka
;
D. Kadam
;
V. Mave
;
M. Makanga
;
S. N. Fontain
;
P. Sugandhavesa
;
A. Avihingsanon
;
L. Nakibuuka
;
H. Nassolo
;
P. Anthony
;
V. Kulkarni
;
M. Nsubuga
;
J. van Wyk
;
J. Rooney
;
Y. van Delft
;
R. Leavitt
;
R. Luk
;
A. Benns
;
L. Hovind
;
A. Shahkolahi
1-Jun-2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
Anchalee Avihingsanon
;
Michael D. Hughes
;
Robert Salata
;
Catherine Godfrey
;
Caitlyn McCarthy
;
Peter Mugyenyi
;
Evelyn Hogg
;
Robert Gross
;
Sandra W. Cardoso
;
Aggrey Bukuru
;
Mumbi Makanga
;
Sharlaa Badal-aesen
;
Vidya Mave
;
Beatrice Wangari Ndege
;
Sandy Nerette Fontain
;
Wadzanai Samaneka
;
Rode Secours
;
Marije Van Schalkwyk
;
Rosie Mngqibisa
;
Lerato Mohapi
;
Javier Valencia
;
Patcharaphan Sugandhavesa
;
Esmelda Montalban
;
Cornelius Munyanga
;
Maganizo Chagomerana
;
Breno R. Santos
;
Nagalingeswaran Kumarasamy
;
Cecilia Kanyama
;
Robert T. Schooley
;
John W. Mellors
;
Carole L. Wallis
;
Ann C. Collier
;
Beatriz Grinsztejn